단백질 어세이 시장 : 제품 유형, 기술, 최종사용자, 용도별 - 세계 예측(2026-2032년)

The Protein Assays Market is projected to grow by USD 5.11 billion at a CAGR of 7.73% by 2032.

Protein Assays Executive Summary

Protein assays are foundational analytical tools for quantifying, characterizing, and comparing proteins across drug discovery, biologics manufacturing, diagnostics, food safety, and academic life sciences. Demand is anchored by validated workflows such as Bradford, BCA, Lowry, UV absorbance, ELISA, Western blotting, capillary electrophoresis, and mass spectrometry-enabled protein analysis.

Market momentum is being driven by biologics pipelines, biosimilar development, precision medicine, proteomics research, and stricter quality-control expectations in regulated laboratories. As FDA, EMA, and ICH guidance continue to emphasize method validation, accuracy, specificity, robustness, and reproducibility, buyers are prioritizing protein assay kits, automated readers, software-integrated workflows, and consumables that reduce variability while supporting high-throughput research.

Transformative Shifts in the Protein Assays Landscape

The protein assays landscape is shifting from manual, endpoint-based testing toward automated, miniaturized, and data-rich analytical systems. Laboratories are adopting microplate readers, multiplex immunoassays, microfluidic sample handling, and integrated LIMS connectivity to reduce sample volumes, improve throughput, and strengthen traceability.

Transformative growth is also linked to biologics and cell and gene therapy development, where accurate protein quantification supports critical quality attributes, potency testing, comparability studies, and process monitoring. Vendors that combine validated chemistries, low-interference reagents, automation compatibility, and digital analytics are positioned to meet demand from contract research organizations, biopharmaceutical manufacturers, clinical laboratories, and translational research institutes.

Cumulative Impact of Artificial Intelligence on Protein Assays

Artificial intelligence is accelerating protein assay interpretation by improving image analysis, plate-read normalization, anomaly detection, assay optimization, and predictive quality control. Machine learning models can identify drift, edge effects, reagent-lot variation, calibration inconsistencies, and outlier wells earlier than manual review, helping laboratories improve reproducibility and reduce repeat testing.

The strongest AI adoption is emerging where protein assays generate large, structured datasets, including high-throughput screening, proteomics, immunoassays, and biologics process analytics. Industry leaders must align AI-enabled platforms with FDA expectations for data integrity, 21 CFR Part 11 electronic records, EU Annex 11, and Good Machine Learning Practice principles to ensure that automation strengthens, rather than compromises, regulatory confidence.

Key Regional Insights Across Protein Assays

Asia-Pacific is expanding rapidly as China, India, Japan, South Korea, Australia, and ASEAN markets invest in biotechnology manufacturing, clinical research, and public health laboratory capacity. Regional demand is supported by biosimilar production, academic proteomics, vaccine development, contract research activity, and cost-sensitive adoption of robust colorimetric and immunoassay kits.

North America remains a leading innovation hub due to large NIH-supported research activity, strong biopharmaceutical R&D, FDA-regulated bioanalytical testing, and extensive CRO infrastructure. Europe benefits from Horizon Europe funding, EMA standards, and advanced academic-industry networks, while Latin America is led by Brazil and Mexico in clinical diagnostics, public health testing, and biomanufacturing. The Middle East is building life science clusters through Saudi Arabia and UAE investment in healthcare localization, genomics, and laboratory modernization, and Africa is gradually expanding diagnostic and research capacity through public health programs, infectious disease surveillance, and university partnerships.

Key Group Insights for Protein Assays Demand

ASEAN demand is shaped by expanding hospital laboratories, vaccine manufacturing, and growing biotechnology hubs in Singapore, Thailand, Malaysia, Indonesia, and Vietnam. GCC countries are investing in laboratory modernization, genomics, healthcare localization, and specialized medical infrastructure, creating opportunities for automated immunoassay and protein quantification platforms.

The European Union offers a mature regulatory and research environment supported by Horizon Europe, CE-marking pathways, clinical laboratory standards, and strong biopharma clusters. BRICS countries are strategically important because China, India, Brazil, Russia, and South Africa combine large patient populations with expanding biosimilar, vaccine, diagnostics, and public-sector research capacity. G7 markets drive premium adoption through advanced R&D, regulated quality systems, and established life science funding, while NATO countries support demand through biodefense, medical readiness, public health preparedness, and infectious disease surveillance infrastructure.

Key Country Insights Shaping Protein Assay Adoption

The United States leads in advanced protein assay adoption through NIH-backed research, FDA-regulated biologics development, and a large CRO and biopharma base. Canada supports growth through university research networks, clinical trial activity, and biologics manufacturing, while Mexico benefits from nearshoring, clinical testing, and pharmaceutical production. Brazil is Latin America's strongest opportunity, supported by public health institutions, vaccine capabilities, and expanding diagnostics infrastructure.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine academic excellence with pharmaceutical, biotechnology, and diagnostic demand, while Russia maintains needs in domestic diagnostics and research despite supply-chain constraints. China and India are high-growth markets for biosimilars, vaccines, CRO services, and proteomics research; Japan and South Korea emphasize precision analytics, high-quality instrumentation, and bioprocess innovation; and Australia remains important for translational research, clinical trials, infectious disease research, and regional life science partnerships.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize assay portfolios that combine validated performance, automation compatibility, low sample consumption, and broad application coverage across drug discovery, biologics QC, diagnostics, and academic research. Clear documentation for sensitivity, specificity, dynamic range, interference resistance, calibration strategy, and reproducibility is essential for regulated and high-throughput buyers.

Companies should also invest in AI-assisted analytics, cloud-connected instruments, sustainable reagent packaging, and training programs that reduce user error. Strategic partnerships with CROs, biomanufacturers, reference laboratories, and university core facilities can accelerate adoption, while regional pricing, application support, and supply-chain resilience can improve penetration in emerging markets without compromising quality standards.

Research Methodology

This executive summary is built on a triangulated research approach using verified secondary sources, regulatory frameworks, product benchmarking, and industry demand signals. Inputs include publicly available guidance from FDA, EMA, ICH, OECD, NIH, WHO, and recognized life science funding programs, combined with analysis of assay technologies, end-user adoption patterns, and regional biotechnology development.

The methodology emphasizes data integrity, cross-validation, and market relevance. Technology trends were assessed across protein quantification chemistries, immunoassays, automated readers, software-enabled analytics, sample preparation, and proteomics workflows, while regional insights were evaluated through research intensity, biopharmaceutical infrastructure, diagnostics demand, public health priorities, and policy-supported life science investment.

Conclusion

Protein assays are evolving from routine laboratory measurements into strategic enablers of biologics innovation, precision diagnostics, quality control, and proteomics discovery. Adoption is supported by rising biopharmaceutical complexity, global research funding, clinical laboratory modernization, and demand for reproducible, validated analytical results.

Future competitiveness will depend on accuracy, throughput, regulatory readiness, automation, data integrity, and AI-enabled decision support. Organizations that deliver reliable assay chemistry with integrated data systems and region-specific commercialization strategies will be best positioned to support growth across mature research economies and fast-expanding emerging life science markets.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Protein Assays Market, by Product Type

• 7.1. Assay Kits & Reagents
  • 7.1.1. Lateral Flow
  • 7.1.2. Microplate Based
• 7.2. Instruments
  • 7.2.1. Lc Ms Systems
  • 7.2.2. Microplate Readers
  • 7.2.3. Spr Systems
• 7.3. Services
  • 7.3.1. Contract Research
  • 7.3.2. Maintenance & Consulting
  • 7.3.3. Training & Support

8. Protein Assays Market, by Technology

• 8.1. Enzyme Linked Immunosorbent Assay
• 8.2. Liquid Chromatography Mass Spectrometry
  • 8.2.1. Orbitrap
  • 8.2.2. Time Of Flight
  • 8.2.3. Triple Quadrupole
• 8.3. Surface Plasmon Resonance
• 8.4. Western Blotting

9. Protein Assays Market, by End User

• 9.1. Academic And Research Institutes
• 9.2. Contract Research Organizations
• 9.3. Hospitals And Diagnostic Laboratories
• 9.4. Pharmaceutical And Biotechnology Companies
  • 9.4.1. Large Pharmaceutical
  • 9.4.2. Small And Medium Pharmaceutical

10. Protein Assays Market, by Application

• 10.1. Disease Research And Diagnostics
  • 10.1.1. Genetic Disorders
  • 10.1.2. Infectious Diseases
  • 10.1.3. Oncology
• 10.2. Drug Discovery And Development
• 10.3. Environmental Testing
• 10.4. Food And Beverage Analysis

11. Protein Assays Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Protein Assays Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Protein Assays Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abcam plc
• 15.2. Abnova Corporation
• 15.3. Agilent Technologies, Inc.
• 15.4. Becton, Dickinson and Company
• 15.5. Beyotime Biotechnology
• 15.6. Bio-Rad Laboratories, Inc.
• 15.7. Bio-Techne Corporation
• 15.8. Cayman Chemical Company
• 15.9. Cell Biolabs, Inc.
• 15.10. Cell Signaling Technology, Inc.
• 15.11. Corning Incorporated
• 15.12. Danaher Corporation
• 15.13. DiaSorin S.p.A.
• 15.14. Enzo Biochem, Inc.
• 15.15. Eurofins Scientific SE
• 15.16. Fujifilm Wako Pure Chemical Corporation
• 15.17. G-Biosciences
• 15.18. Lonza Group Ltd
• 15.19. Merck KGaA
• 15.20. New England Biolabs, Inc.
• 15.21. Promega Corporation
• 15.22. Proteintech Group, Inc.
• 15.23. QIAGEN N.V.
• 15.24. Randox Laboratories Ltd
• 15.25. RayBiotech, Inc.
• 15.26. Revvity, Inc.
• 15.27. Roche Holding AG
• 15.28. Sartorius AG
• 15.29. Takara Bio Inc.
• 15.30. Thermo Fisher Scientific Inc.